Ovarian Cancer Conference

Transcription

1 Memorial Sloan Kettering Cancer Center is pleased to announce: State of the Art Ovarian Cancer Conference Thursday, October 6,

2 Course Overview Advances in women s health research provide important opportunities to enhance the screening and prevention of ovarian cancer. New modalities in the treatment of the disease provide the ability to individualize therapy, accomplish best clinical outcomes, and optimize the patient experience. Educational Objectives This course is designed to present the most current information on ovarian cancer with the goal of advancing the prevention, screening and treatment for ovarian cancer. Discuss new genetic panel testing and its implication, results of recent ovarian cancer screening trial, and strategies for ovarian cancer risk-reduction. Present new algorithms for imaging and surgical case selection. Evaluate emerging opportunities in clinical trial options, individualized treatment, and enhanced patient experience. Target Audience All clinicians, scientists and advocates interested in women s health, and in optimizing the prevention, screening and treatment for ovarian cancer. Clinicians including OB/GYNs, surgical/medical/gynecologic oncologists, primary care physicians, physician assistants, nurse practitioners, nurses, fellows and residents and other healthcare professionals are welcome. Given the importance of the advocacy community, patients and supporters are invited to attend.

3 Course Faculty MSK COURSE DIRECTORS Ginger J. Gardner, MD, FACOG Associate Attending Surgeon, Gynecology Service; Section of Ovarian Cancer Surgery; Lead Physician, Gynecology Disease Management Team Alliance; Co-Chair, Institutional Patient Flow Committee Kara Long Roche, MD, MSc, FACOG Assistant Attending Surgeon, Gynecology Service; Section of Ovarian Cancer Surgery MSK FACULTY Nadeem Abu-Rustum, MD Chief, Gynecology Service; Vice Chair for Technology Development, Department of Surgery; Avon Chair in Gynecologic Oncology Carol Aghajanian, MD Chief, Richard R. Barakat, MD, FACS Deputy Physician-in-Chief, Regional Care Network and MSK Cancer Alliance; Ronald O. Perelman Chair in Gynecologic Surgery Carol L. Brown, MD Director, Office of Diversity Programs in Clinical Care, Research and Training; Attending Surgeon, Gynecology Service Karen A. Cadoo, MD Dennis S. Chi, MD, FACOG, FACS Deputy Chief and Head, Section of Ovarian Cancer Surgery, Attending Surgeon, Gynecology Service, Department of Surgery Martee L. Hensley, MD Attending Physician, David Hyman, MD Director, Developmental Therapeutics; Elizabeth Jewell, MD Associate Attending Surgeon, Gynecology Service Jason A. Konner, MD Chief, Monmouth Medical Oncology; Associate Attending Physician, MSK ALLIANCE MEMBERS Rick Boulay, MD Chief, Division of Gynecologic Oncology Lehigh Valley Health Network Jeff Boyd, PhD Director, Translational Research and Genomic Medicine Miami Cancer Institute Baptist Health South Florida Mario M. Leitao, Jr., MD Fellowship Director, Attending Surgeon, Gynecology Service; Director, Minimal Access and Robotic Surgery Program, Department of Surgery Roisin E. O'Cearbhaill, MD Rachel Grisham, MD Mark E. Robson, MD Clinic Director, Clinical Genetics Service; Attending Physician, Clinical Genetics Service, Breast Medicine Service Paul Sabbatini, MD Deputy Physician-in-Chief for Clinical Research, Attending Physician, Evis Sala, MD, PhD Chief, Body Imaging Service Yukio Sonoda, MD, FACOG, FACS Attending Surgeon, Gynecology Service, Section of Ovarian Cancer Surgery Robert Soslow, MD Director, Gynecologic Pathology; Director, Gynecologic Pathology Fellowship Program William P. Tew, MD Associate Attending Physician, Dmitriy Zamarin, MD, PhD Oliver Zivanovic, MD, PhD Director, Innovative Surgical Technology, Assistant Attending Surgeon, Gynecology Service, Section of Ovarian Cancer Surgery, Department of Surgery Jonathan Cosin, MD Chief, Gynecologic Oncology, The Hospital of Central Connecticut Middlesex Hospital Surgical Alliance Program

4 State of the Art Ovarian Cancer Conference Thursday, October 6, 2016 Scientific Agenda 7:30 am REGISTRATION & BREAKFAST 8:00 am Welcoming Remarks Nadeem Abu-Rustum, MD Dennis S. Chi, MD, FACOG, FACS 8:15 am Alliance Participation and Expansion Richard R. Barakat MD, FACS SESSION I Ovarian Cancer Genetics, Screening and Prevention Jonathan Cosin, MD 8:30 am Identification and Evaluation of the High Risk Patient: What should be included in Routine Women s Health Care? Kara Long Roche, MD, MSc, FACOG 8:50 am Updates from UKTOCS Screening Trial Jeff Boyd, PhD 9:10 am Panel Testing: the Evolving Landscape of Genetic Tests and Implications Mark E. Robson, MD 9:40 am What is the Role of the Fallopian Tube in Ovarian Cancer Development? Robert Soslow, MD 10:00 am Debate: Risk-Reducing Surgical Options PRO: BSO is the Way to Go Mario M. Leitao, Jr., MD CON: Salpingectomy is the New Standard Kara Long Roche, MD, MSc, FACOG 10:15 am Discussion 10:30 am BREAK SESSION II Management of Newly Diagnosed Ovarian Cancer S Carol L. Brown, MD 10:45 am MSKCC Resectability Algorithm for Primary Debulking Surgery Oliver Zivanovic, MD, PhD 11:00 am Surgical Progress for Newly Diagnosed Ovarian Cancer and Outcomes Dennis S. Chi, MD, FACOG, FACS 11:30 am Precision Imaging: CT Scan and Protocol Enhancement Evis Sala, MD, PhD 11:50 am Discussion 12:00 pm LUNCH

5 State of the Art Ovarian Cancer Conference Thursday, October 6, 2016 SESSION III Adjuvant Therapy Rachel Grisham, MD 1:00 pm New Treatment Options: Dose Dense vs Intraperitoneal Treatment Roisin E. O Cearbhaill, MD 1:30 pm Targeted Therapy for Ovarian Cancer: Flying with Biologics Jason A. Konner, MD 2:00 pm The New Horizon in Immunotherapy Dmitriy Zamarin, MD, PhD 2:20 pm Discussion 2:30 pm BREAK SESSION IV Recurrent Disease Rick Boulay, MD 2:45 pm Surgery for Recurrent Disease: Optimizing Case Selection and Outcomes Ginger J. Gardner, MD, FACOG 3:00 pm HIPEC Chemo Wash Current Data and Prospective Trial Design Oliver Zivanovic, MD, PhD 3:15 pm Pathway to an Enhanced Recovery Yukio Sonoda, MD, FACOG, FACS 3:30 pm Optimal Chemotherapy for Recurrent Disease Paul Sabbatini, MD 3:45 pm BREAK SESSION V Treatment and Quality of Life Martee L. Hensley, MD 4:00 pm Debate: Clinical Trial Options Traditional Clinical Trials have Strongest Rationale Carold Aghajanian, MD New Basket Trials and Targeted Treatments are Ideal David Hyman, MD 4:30 pm Factoring in Age: Chemotherapy and Surgery William P. Tew, MD 4:45 pm Opportunities in Exercise Oncology Karen A. Cadoo, MD 5:00 pm Patient Reported Outcomes Elizabeth Jewell, MD 5:15 pm Closing Remarks Ginger J. Gardner, MD, FACOG 5:30 pm Cocktail Reception

6 Registration EARLY Before 9/9/16 GENERAL After 9/9/16 MDs, PhDs and DOs $300 $350 MSK Alliance and MSK Alumni $200 $250 Residents, Fellows, RNs and Other Healthcare Providers $100 $150 Industry Members* $800 $800 REGISTER ONLINE AT: Special CME Discount For discounted registration in both the Ovarian Course and the Intraoperative Imaging Course taking place at MSK, please visit the conference website for more information. REGISTRATION Registration includes continental breakfast, lunch, and refreshment breaks. Please contact us at least one week prior to the course if you have any special dietary needs. Registration is complimentary for MSK staff who wish to attend this course. However, you must register online by visiting the Continuing Medical Education page on. COURSE DESIGN This course is comprised of lectures and interactive audience participation encouraging the intellectual exchange of ideas between faculty and participants. ACCOMMODATIONS For information on hotels in the area of MSKCC with discounted rates, please visit: ACCREDITATION STATEMENT MSK is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AMA CREDIT DESIGNATION STATEMENT MSK designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credits. Physicians should only claim credit commensurate with the extent of their participation in the activity. The AMA has determined that physicians not licensed in the United States but who participate in this CME activity are eligible for 7.25 AMA PRA Category 1 Credits. FACULTY DISCLOSURE It is the policy of MSK to make every effort to insure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it sponsors as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity sponsored by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational. CONTACT Continuing Medical Education Memorial Sloan Kettering Cancer Center 633 Third Avenue, 12th Floor New York, NY cme@mskcc.org *Industry Members: Registration is for educational purposes only. Marketing, sales, and promotion of products and services are prohibited at CME activities.